Intellia Therapeutics, Inc. (NTLA) News
Filter NTLA News Items
NTLA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NTLA News Highlights
- For NTLA, its 30 day story count is now at 5.
- Over the past 20 days, the trend for NTLA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE, AAPL and ADD are the most mentioned tickers in articles about NTLA.
Latest NTLA News From Around the Web
Below are the latest news stories about INTELLIA THERAPEUTICS INC that investors may wish to consider to help them evaluate NTLA as an investment opportunity.
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket PharmaceuticalsIntellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for hereditary afflictions that have so far proved beyond the reach of medical science. The case for Rocket Pharmaceuticals is that it could be commercializing its first medicines in rare disease markets where there aren't any other options. It'll soon enter phase 2 clinical trials with its candidate to cure or treat Danon disease, a lethal hereditary heart condition that affects up to 30,000 people in the U.S. and E.U. Its program for Fanconi anemia is on track for submission to regulators and commercialization in the coming quarters, potentially treating up to 275 people per year. |
Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could DoubleCathie Wood is known for her propensity to buy growth stocks that have the chance to disrupt their industries while also making early investors rich. As with many of her other picks, Wall Street analysts estimate, on average, that both stocks could more than double within a year, though both lost value and underperformed the market over the last 12 months. As an early-stage biotech stock years from having any shot at selling a medicine, Intellia Therapeutics is a high-risk, high-reward style investment that's a great fit for Cathie Wood. |
Cathie Wood Is Buying This Stock Hand Over Fist. Should You?Superstar investor Cathie Wood is increasing her bet on a cutting-edge technology that could transform the treatment of many diseases. Wood has been progressively increasing her stake in specialist Intellia Therapeutics (NASDAQ: NTLA) since December. The company's stock has dropped about 17% since its peak in July, so Wood clearly saw this as an opportunity to add to her position in the biotech company. |
‘Market May Be Broadening Out’: Cathie Wood Loads Up on These 2 Innovation StocksPerceived wisdom goes that the way to outperform the market this year has been by leaning into the Magnificent Seven stocks (AAPL, AMZN, GOOGL, META, MSFT, NVDA, TSLA). These market leaders – all tech giants – are seen as being responsible for the market’s rally, but hold that thought, says Ark Invest CEO Cathie Wood. These names don’t take up much room in Wood’s flagship Ark Innovation ETF, yet the fund, with its focus on bold, innovative stocks, still managed to beat the main indexes’ performa |
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThere is some good news and bad news for fans of Cathie Wood. The good news for the co-founder CEO of the Ark Invest family of exchange-traded funds (ETFs) is that her largest fund -- with more than $9 billion in assets -- is rolling in 2023. Wood added to her existing stakes in Palantir Technologies (NYSE: PLTR), Intellia Therapeutics (NASDAQ: NTLA), and Accolade (NASDAQ: ACCD) on Thursday. |
The 3 Most Promising Biotech Stocks to Own NowThese top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential. |
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks AgainOn the heels of Nvidia's (NASDAQ: NVDA) recent second-quarter earnings release, CEO Cathie Wood's Ark Invest firm continued to trim holdings in the semiconductor stock. The investment firm sold 3,952 shares of Nvidia from its Ark Genomic Revolution ETF on Aug. 24 -- working out to approximately $1.9 million. While Nvidia was the only stock that Ark sold that day, Wood's company also bought five stocks in the daily trading session. |
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth StocksCEO Cathie Wood's Ark Invest firm continues to trim its holdings in Shopify (NYSE: SHOP). The company regularly publishes updates on holdings in its exchange-traded funds (ETFs), and its latest update showed that it sold 48,313 shares of the e-commerce services stock for its ARK Next Generation Internet ETF (NYSEMKT: ARKW) and 120,022 shares of the stock from its Ark Fintech Innovation ETF (NYSEMKT: ARKF) on Aug. |
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall StreetThe average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Can these biotechs meet these expectations, or is Wall Street too optimistic? Editas Medicine has yet to find this partner, but it is making headway with another potential therapy, EDIT-301. |
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline UpdateIntellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline. |